SB02024

• Description:

  SB02024 is a potent and orally active VPS34 inhibitor. SB02024 inhibits Vps34 kinase activity. SB02024 induces CCL5 and CXCL10 via STAT1/IRF7. SB02024 shows anticancer activity[1][2][3].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  CXCR; PI3K; STAT

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Immunology/Inflammation; JAK/STAT Signaling; PI3K/Akt/mTOR; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/sb02024.html

• Purity:

  99.70

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1C=C(N2[C@H](C)COCC2)C=C(N3[C@@H](C(F)(F)F)CCCC3)N1

• Molecular Formula:

  C16H22F3N3O2

• Molecular Weight:

  345.36

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Noman MZ, et al. Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy. Sci Adv. 2020 Apr 29;6 (18) :eaax7881.|[2]Yu Y, et al. Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy. Mol Oncol. 2024 Mar 20.|[3]Bassam Claude JANJI, et al. Biomarker. Patent WO2020008046 A1.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  STAT1; Vps34

• CAS Number:

  [2126737-28-6]